Commitments and Contingencies	6 Months Ended
Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7. Commitments and Contingencies In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $122,312 and $198,772 in during the three and six months ended June 30, 2020 and, $85,175 and $161,775 during the three and six months ended June 30, 2019, respectively. Dr. Gerlach, from whom the Company purchased the CellMist^TM System and SkinGun^TM technologies, is a principal of StemCell Systems. On June 3, 2019, the Company entered into a Charitable Gift Agreement with the University of Pittsburgh (“University”), pursuant to which the Company committed to provide a charitable donation to the University in the agreement amount of $250,000 (the “Grant”). The Company paid the Grant in four installments with the first payment made in July 2019. During the three and six months ended June 30, 2020 the Company made payments totaling $0 and $62,500, respectively. During each of the three and six months ended June 30, 2019 the Company made payments totaling $62,500. At June 30, 2020, the balance remaining under this gift was $62,500 which has been included in accounts payable and accrued liabilities in the accompanying condensed consolidated balance sheets. Subsequent to the quarter ending June 30, 2020 the Company paid $62,500 fulfilling its obligation under the Grant. Dr. Gerlach, from whom the Company purchased the CellMist^TM System and SkinGun^TM technology, is a professor at the University. See also “Note 8. Related Party Transactions.”

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Note 7. Commitments and Contingencies

In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $122,312 and $198,772 in during the three and six months ended June 30, 2020 and, $85,175 and $161,775 during the three and six months ended June 30, 2019, respectively. Dr. Gerlach, from whom the Company purchased the CellMist^TM System and SkinGun^TM technologies, is a principal of StemCell Systems.

On June 3, 2019, the Company entered into a Charitable Gift Agreement with the University of Pittsburgh (“University”), pursuant to which the Company committed to provide a charitable donation to the University in the agreement amount of $250,000 (the “Grant”). The Company paid the Grant in four installments with the first payment made in July 2019. During the three and six months ended June 30, 2020 the Company made payments totaling $0 and $62,500, respectively. During each of the three and six months ended June 30, 2019 the Company made payments totaling $62,500. At June 30, 2020, the balance remaining under this gift was $62,500 which has been included in accounts payable and accrued liabilities in the accompanying condensed consolidated balance sheets. Subsequent to the quarter ending June 30, 2020 the Company paid $62,500 fulfilling its obligation under the Grant. Dr. Gerlach, from whom the Company purchased the CellMist^TM System and SkinGun^TM technology, is a professor at the University.

See also “Note 8. Related Party Transactions.”